Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 104.07 +0.25 (+0.24%) Streaming Delayed Price Updated: 9:30 AM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ligand Pharm < Previous 1 2 3 4 5 6 Next > Ligand and GSK Expand Global Collaboration and License Agreement December 21, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire Meme Stock Breakdown December 14, 2021 There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania. Via Talk Markets Ligand Pharmaceuticals Sees RS Rating Rise To 92 November 11, 2021 A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. Via Investor's Business Daily Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company November 10, 2021 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb... Via Benzinga Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript November 10, 2021 LGND earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Recap: Ligand Pharmaceuticals Q3 Earnings November 09, 2021 Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement.... Via Benzinga Ligand Reports Third Quarter 2021 Financial Results November 09, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company November 09, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data November 09, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... Via Benzinga Ligand to Report Third Quarter Financial Results on November 9, 2021 October 26, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More November 08, 2021 Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... Via Benzinga Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals October 21, 2021 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC). The agreement grants... Via Benzinga Exposures COVID-19 Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™ October 21, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Stock Shows Rising Price Performance September 22, 2021 A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance. Via Investor's Business Daily Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating September 20, 2021 Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82. Via Investor's Business Daily Why Digital Turbine's Stock Is Trading Higher Today August 31, 2021 Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400. Digital Turbine will replace ... Via Benzinga Topics Stocks Exposures US Equities Digital Turbine Added To S&P MidCap 400 Index August 31, 2021 Media and mobile communications company Digital Turbine Inc (NASDAQ: Via Benzinga Topics Stocks Exposures US Equities The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical August 31, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... Via Benzinga Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma August 30, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy August 16, 2021 From Ligand Pharmaceuticals Via Business Wire What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months August 12, 2021 Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy... Via Benzinga Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript July 30, 2021 LGND earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Ligand Reports Second Quarter 2021 Financial Results July 29, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs July 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Exposures Product Safety The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More July 25, 2021 Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... Via Benzinga Exposures Product Safety Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458 July 21, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes July 19, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs July 18, 2021 Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... Via Benzinga Exposures Product Safety Ligand to Report Second Quarter Financial Results on July 29, 2021 July 16, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors July 14, 2021 From Ligand Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.